SER
Serina Therapeutics, Inc.
Healthcare — Biotechnology
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Price History
Fundamentals
| Market Cap | $30.00M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.90 |
| EPS (TTM) | $-2.00 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -221.93% |
| Debt/Equity | 18.93 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $9.50 |
| Analysts | 2 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 46.9 |
| Beta | 0.03 |
| SMA 20 | $2.08 |
| SMA 40 | $1.98 |
| 52-Week High | $7.92 |
| 52-Week Low | $1.22 |
| 50-Day Avg | $1.96 |
| 200-Day Avg | $2.54 |
| Avg Volume | 85.4K |
| Volume | 69.8K |
Performance Analysis
BULLISHSER shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Aug 01, 2026 04:12 UTC
Back to Screener Export Report